The range of effects caused by rhinoviruses – the pathogens responsible for the common cold – motivated scientists at Yale University to study the human nasal epithelium and uncover a previously undescribed defense mechanism. The interferon-mediated protective response in these cells can limit infection, whereas a maladaptive response tends to worsen it. Based on these findings, the researchers have identified potential therapeutic targets to reduce inflammation associated with rhinovirus infection. Read More
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell engager consisting of two nanobody domains targeting HER2 and T-cell receptor (TCR) fused to an Fc region harboring the F234A and L235A mutations to inhibit effector function. Read More
Smartbax GmbH has in-licensed a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary pipeline of small-molecule antibiotics. Read More
Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis. Read More
The University of Michigan has disclosed pyrrolo[1,2-a]-azocine analogues acting as as inhibitor of apoptosis proteins (IAP) inhibitors. As such, they are reported to be potentially useful for the treatment of AIDS, cancer, infections, psoriasis, multiple sclerosis, vascular disorders, inflammatory disorders and autoimmune diseases. Read More
Ascletis Pharma Inc. has selected ASC-37 injection, a next-generation, once-monthly, subcutaneously administered glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide receptor (GIPR)/ glucagon receptor (GCGR) triple peptide agonist, as a clinical development candidate. Read More
Leigh syndrome is a fatal pediatric neurodegenerative disorder caused by mitochondrial dysfunction, most often due to defects in the mitochondrial respiratory chain. The Ndufs4 knockout (Ndufs4 KO) mouse is an established model of the disease, as loss of the NDUFS4 subunit leads to complex I (CI) deficiency and reproduces the neurological decline and pathology seen in affected children. Researchers from The Children’s Hospital of Philadelphia Research Institute and collaborators described how NV-354, a water-soluble prodrug of succinate, may mitigate this mitochondrial dysfunction. Read More
Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis. Read More
Increasing evidence exists regarding receptor-interacting protein kinase 1 (RIPK1), a necroptosis regulator, being involved in inflammation and fibrosis in chronic liver disorders. The relationship between necroptosis and the inhibition of RIPK1 were investigated in primary sclerosing cholangitis (PSC) in a recently published study using clinical specimens from patients. Read More
The University of Washington has divulged antibody-drug conjugates (ADCs) comprising an antibody targeting HER2 (erbB2) linked to monomethyl auristatin E (MMAE) through a linker. They are described as useful for the treatment of cancer. Read More
Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors have been reported in several Daewoong Pharmaceutical Co. Ltd. patents. They are described as potentially useful for the treatment of cancer and autoimmune diseases. Read More
Copper is an essential trace element with critical roles in several biological processes; therefore, its levels are tightly regulated by multiple mechanisms. Researchers from Sun Yat-Sen University (Guangzhou, China) and collaborators recently described the design of a series of novel copper ionophores with varying n-alkyl chain lengths. Read More
